Medical Condition News

RSS

Artisan Pharma enrolls 750 patients in Phase 2b study of ART-123 in sepsis patients with DIC

Artisan Pharma, Inc., a private biopharmaceutical company dedicated to bringing best-in-class critical care therapeutics to patients, today announced the completion of patient enrollment in its Phase 2b study of ART-123 (Recomodulin® - recombinant human thrombomodulin) in sepsis patients with disseminated intravascular coagulation (DIC). The clinical trial was a randomized, double-blind, placebo-controlled Phase 2b study to assess the safety and efficacy of ART-123 in patients with sepsis and DIC.

30 Apr 2010

Continuing education lectures on adult glioblastoma to be held at all U.S. healthcare centers

Adult glioblastoma continues to be a difficult disease to treat, so healthcare professionals must have the most up-to-date information regarding optimal methods for diagnostic imaging and treatment of these tumors. Awareness of novel agents in clinical trials is also critical to providing the best care.

30 Apr 2010

EndoChoice granted FDA marketing clearance for BONASTENT Esophageal and Biliary Stent platforms

EndoChoice, Inc. today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its BONASTENT® Fully Covered Esophageal Stent for the treatment of malignant esophageal obstructions, and its BONASTENT Uncovered Biliary Stent for the treatment of malignant biliary obstructions.

30 Apr 2010

NeoGenomics first-quarter revenue up 22%

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services today reported its results for the first quarter 2010.

29 Apr 2010

6 transplant surgeons perform 16 surgeries over 3 days in landmark domino paired kidney exchange

Chicago resident Maria Isho had been waiting for over nine years for a kidney transplant. Her body was highly sensitized, meaning that her body had built up antibodies in the blood, which made it difficult for her to find a match. To stay healthy, she endured a grueling dialysis regimen which diminished her quality of life and left her feeling physically drained.

29 Apr 2010

Provectus reports on end-of-Phase 2 meeting with FDA on licensure of PV-10 for metastatic melanoma

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that it has held an end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) to seek consensus on clinical program scope and endpoints for licensure of PV-10 for metastatic melanoma. The meeting was held at the Agency's White Oak Campus in Silver Spring, MD.

29 Apr 2010

The OCD Project challenges six severe OCD sufferers to face fears in a bold move to better their lives

Obsessive-Compulsive Disorder is a disorder of the brain where people experience obsessive thoughts, images, ideas or impulses – and they can't get past them. The day-to-day existence for severe OCD sufferers is dire. Untreated, they lead lives of self-punishment, fear and isolation that can result in job loss, broken families, bankruptcy and in some cases death.

29 Apr 2010

22% of Canadians have contemplated or attempted suicide

On the eve of Children's Mental Health Week (May 2 to 8), Kinark Child and Family Services, a not-for-profit child and youth mental health organization in Ontario that provides expert help to children, youth and their families, released the results of a nation-wide poll that found that one in five Canadians has contemplated or attempted suicide. The online survey was conducted between April 12 and 14, 2010 with a nationally representative sample of 1,000 adults. The results are accurate to within +/- 3.1 percent at the 95% confidence level.

29 Apr 2010

China Medical Technologies' AUTOMAGLIA 90 analyzer and Down Syndrome Screening receive SFDA approval

China Medical Technologies, Inc., a leading China-based advanced in-vitro diagnostic company, today announced that it received approval for its AUTOMAGLIA 90 fully-automated ECLIA analyzer as well as Down Syndrome screening kit from the State Food and Drug Administration of China.

29 Apr 2010

AVEO Pharmaceuticals reports net loss of $14.4 million for first-quarter 2010

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced financial results for the quarter ended March 31, 2010, provided an update on progress towards achievement of 2010 goals as well as 2010 financial guidance.

29 Apr 2010

Power3 Medical Products to present four abstracts at International Congress of Alzheimer's Disease

Power3 Medical Products, Inc. announced that four abstracts were accepted for presentation to the annual meeting of the International Congress of Alzheimer's Disease on July 12, 2010 in Honolulu, Hawaii. The presentations will cover results from protein biomarker discovery, drug response, test development, and ongoing clinical validation trials of the NuroPro AD biomarkers and blood test for Alzheimer's disease.

29 Apr 2010

Obese children metabolize caffeine and dextromethorphan at different rates than healthy weight children

Researchers from the University of Minnesota College of Pharmacy have provided the first evidence-based data on changes in drug metabolism in obese children as compared to healthy weight children.

29 Apr 2010

87% of people risk dangerous levels of skin damage

Nearly nine out of ten people (87 per cent) could be risking dangerous levels of skin damage, which can lead to skin cancer, because they are either not using the right amount of sunscreen, not sure of the amount they use or are not using any at all - according to a new survey by Superdrug and Cancer Research UK.

29 Apr 2010

Science behind ME

Juliet Chenery-Robson decided to use photography to make people look at Myalgic Encephalopathy in a different light when her 18-year-old daughter Emilia was diagnosed with the illness five years ago.

29 Apr 2010

Nanotechnology for study of individual molecule interaction in live cells

A University of Alberta-led research team has taken a major step forward in understanding how T cells are activated in the course of an immune response by combining nanotechnology and cell biology. T cells are the all important trigger that starts the human body's response to infection.

29 Apr 2010

Genetic test to predict newborns requiring hospital readmission shortly after birth

The results of two separate research studies taking place at Children's Mercy Hospitals and Clinics will help physicians use genetic testing to prevent complications, and ease the worry of new parents by predicting in advance which newborns may require readmission to the hospital shortly after birth. The studies also will help physicians identify which of their young patients are likely to respond well - or not - to steroid therapy for asthma.

29 Apr 2010

Removing unruptured AVM decreases risk of hemorrhaging, provides better outcomes to patients

Individuals diagnosed with a brain arteriovenous malformation, an abnormal tangle of arteries and veins, are at an increased risk of vessel rupture and bleeding that can cause stroke and permanent brain damage.

29 Apr 2010

Cardiac Science responds to FDA communications on AED recall

Cardiac Science Corporation, responded to FDA communications released yesterday related to the AED recall first announced in November, 2009. The Agency communication specifies additional affected models and offers further guidance to users of AEDs affected by potential component defects in some of the Company's AEDs.

29 Apr 2010

Panel finds insufficient evidence to support preventive measures for cognitive decline, Alzheimer's disease

Many preventive measures for cognitive decline and for preventing Alzheimer's disease-mental stimulation, exercise, and a variety of dietary supplements-have been studied over the years. However, an independent panel convened this week by the National Institutes of Health determined that the value of these strategies for delaying the onset and/or reducing the severity of decline or disease hasn't been demonstrated in rigorous studies.

29 Apr 2010

Albireo to present study results of A3309 in patients with chronic constipation at 2010 DDW annual meeting

Albireo today announced that additional clinical data will be reported from a recent study assessing the safety, tolerability and efficacy of A3309 in patients with chronic constipation. A3309 is a first-in-class investigational compound for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic constipation (CC). The results will be presented during the 2010 Digestive Disease Week (DDW) annual meeting being held in New Orleans, US.

29 Apr 2010

Medical Condition News

Artisan Pharma enrolls 750 patients in Phase 2b study of ART-123 in sepsis patients with DIC

Continuing education lectures on adult glioblastoma to be held at all U.S. healthcare centers

EndoChoice granted FDA marketing clearance for BONASTENT Esophageal and Biliary Stent platforms

NeoGenomics first-quarter revenue up 22%

6 transplant surgeons perform 16 surgeries over 3 days in landmark domino paired kidney exchange

Provectus reports on end-of-Phase 2 meeting with FDA on licensure of PV-10 for metastatic melanoma

The OCD Project challenges six severe OCD sufferers to face fears in a bold move to better their lives

22% of Canadians have contemplated or attempted suicide

China Medical Technologies' AUTOMAGLIA 90 analyzer and Down Syndrome Screening receive SFDA approval

AVEO Pharmaceuticals reports net loss of $14.4 million for first-quarter 2010

Power3 Medical Products to present four abstracts at International Congress of Alzheimer's Disease

Obese children metabolize caffeine and dextromethorphan at different rates than healthy weight children

87% of people risk dangerous levels of skin damage

Science behind ME

Nanotechnology for study of individual molecule interaction in live cells

Genetic test to predict newborns requiring hospital readmission shortly after birth

Removing unruptured AVM decreases risk of hemorrhaging, provides better outcomes to patients

Cardiac Science responds to FDA communications on AED recall

Panel finds insufficient evidence to support preventive measures for cognitive decline, Alzheimer's disease

Albireo to present study results of A3309 in patients with chronic constipation at 2010 DDW annual meeting

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Latest News